KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest & Investment Income: 2015-2023

Historic Interest & Investment Income for Sarepta Therapeutics (SRPT) over the last 9 years, with Dec 2023 value amounting to $36.3 million.

  • Sarepta Therapeutics' Interest & Investment Income rose 9506.32% to $9.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $16.5 million, marking a year-over-year increase of 4557.63%. This contributed to the annual value of $36.3 million for FY2023, which is 119.90% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Interest & Investment Income of $36.3 million as of FY2023, which was up 119.90% from $16.5 million recorded in FY2022.
  • Over the past 5 years, Sarepta Therapeutics' Interest & Investment Income peaked at $36.3 million during FY2023, and registered a low of $354,000 during FY2021.
  • In the last 3 years, Sarepta Therapeutics' Interest & Investment Income had a median value of $16.5 million in 2022 and averaged $17.7 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 88.08% in 2021, then spiked by 4,557.63% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Interest & Investment Income (Yearly) stood at $7.2 million in 2019, then slumped by 58.97% to $3.0 million in 2020, then slumped by 88.08% to $354,000 in 2021, then soared by 4,557.63% to $16.5 million in 2022, then skyrocketed by 119.90% to $36.3 million in 2023.